Cameron, Lindsay P. https://orcid.org/0000-0002-8420-7898
Tombari, Robert J. https://orcid.org/0000-0002-6561-8181
Lu, Ju
Pell, Alexander J. https://orcid.org/0000-0003-4463-4761
Hurley, Zefan Q.
Ehinger, Yann
Vargas, Maxemiliano V.
McCarroll, Matthew N.
Taylor, Jack C. https://orcid.org/0000-0002-6431-9956
Myers-Turnbull, Douglas
Liu, Taohui
Yaghoobi, Bianca
Laskowski, Lauren J.
Anderson, Emilie I.
Zhang, Guoliang
Viswanathan, Jayashri https://orcid.org/0000-0002-1293-827X
Brown, Brandon M.
Tjia, Michelle
Dunlap, Lee E.
Rabow, Zachary T. https://orcid.org/0000-0001-6213-4950
Fiehn, Oliver https://orcid.org/0000-0002-6261-8928
Wulff, Heike https://orcid.org/0000-0003-4437-5763
McCorvy, John D. https://orcid.org/0000-0001-7555-9413
Lein, Pamela J. https://orcid.org/0000-0001-7665-7584
Kokel, David
Ron, Dorit
Peters, Jamie https://orcid.org/0000-0002-7573-6384
Zuo, Yi https://orcid.org/0000-0001-9020-0003
Olson, David E. https://orcid.org/0000-0002-4517-0543
Article History
Received: 17 January 2020
Accepted: 30 October 2020
First Online: 9 December 2020
Competing interests
: D.E.O. is the president and chief scientific officer of Delix Therapeutics. Delix Therapeutics has licensed TBG-related technology from the University of California, Davis.